Table_2_Mechanism-Based Biomarker Prediction for Low-Grade Inflammation in Liver and Adipose Tissue.pdf
Metabolic disorders, such as obesity and type 2 diabetes have a large impact on global health, especially in industrialized countries. Tissue-specific chronic low-grade inflammation is a key contributor to complications in metabolic disorders. To support therapeutic approaches to these complications, it is crucial to gain a deeper understanding of the inflammatory dynamics and to monitor them on the individual level. To this end, blood-based biomarkers reflecting the tissue-specific inflammatory dynamics would be of great value. Here, we describe an in silico approach to select candidate biomarkers for tissue-specific inflammation by using a priori mechanistic knowledge from pathways and tissue-derived molecules. The workflow resulted in a list of candidate markers, in part consisting of literature confirmed biomarkers as well as a set of novel, more innovative biomarkers that reflect inflammation in the liver and adipose tissue. The first step of biomarker verification was on murine tissue gene-level by inducing hepatic inflammation and adipose tissue inflammation through a high-fat diet. Our data showed that in silico predicted hepatic markers had a strong correlation to hepatic inflammation in the absence of a relation to adipose tissue inflammation, while others had a strong correlation to adipose tissue inflammation in the absence of a relation to liver inflammation. Secondly, we evaluated the human translational value by performing a curation step in the literature using studies that describe the regulation of the markers in human, which identified 9 hepatic (such as Serum Amyloid A, Haptoglobin, and Interleukin 18 Binding Protein) and 2 adipose (Resistin and MMP-9) inflammatory biomarkers at the highest level of confirmation. Here, we identified and pre-clinically verified a set of in silico predicted biomarkers for liver and adipose tissue inflammation which can be of great value to study future development of therapeutic/lifestyle interventions to combat metabolic inflammatory complications.
History
References
- https://doi.org//10.1530/JOE-15-0219
- https://doi.org//10.1084/jem.20190669
- https://doi.org//10.3389/fped.2014.00148
- https://doi.org//10.1111/ajt.14756
- https://doi.org//10.4049/jimmunol.174.9.5789
- https://doi.org//10.1172/JCI111044
- https://doi.org//10.1002/dmrr.3050
- https://doi.org//10.1016/s0009-8981%2899%2900105-9
- https://doi.org//10.1017/S0029665112000092
- https://doi.org//10.3389/fimmu.2013.00289
- https://doi.org//10.1016/j.bbalip.2020.158792
- https://doi.org//10.1016/j.molimm.2004.03.015
- https://doi.org//10.3389/fphys.2015.00383
- https://doi.org//10.1515/hsz-2017-0131
- https://doi.org//10.1006/bcmd.2001.0415
- https://doi.org//10.1146/annurev-immunol-031210-101322
- https://doi.org//10.1210/jc.2003-030742
- https://doi.org//10.1530/EJE-16-0940
- https://doi.org//10.3233/CH-151928
- https://doi.org//10.1038/nature05485
- https://doi.org//10.1038/nature21363
- https://doi.org//10.1038/nri2449
- https://doi.org//10.1042/BSR20190395
- https://doi.org//10.1016/j.cbpa.2006.05.014
- https://doi.org//10.1186/1476-5926-2-S1-S12
- https://doi.org//10.1016/j.jss.2016.09.041
- https://doi.org//10.3389/fphar.2018.00341
- https://doi.org//10.2147/VHRM.S103877
- https://doi.org//10.1016/1357-2725%2896%2900032-5
- https://doi.org//10.1111/imr.12616
- https://doi.org//10.1038/sj.bjc.6603051
- https://doi.org//10.1371/journal.pcbi.1002375
- https://doi.org//10.1371/journal.pone.0222032
- https://doi.org//10.1186/gb-2007-8-9-r200
- https://doi.org//10.18773/austprescr.2014.061
- https://doi.org//10.1160/TH15-08-0687
- https://doi.org//10.1001/jama.2009.976
- https://doi.org//10.2337/db20-0585
- https://doi.org//10.1093/toxsci/kfab003
- https://doi.org//10.1016/j.thromres.2011.10.021
- https://doi.org//10.1186/s13059-014-0550-8
- https://doi.org//10.1016/j.semcdb.2007.07.003
- https://doi.org//10.1186/s12944-020-1199-9
- https://doi.org//10.1517/17530059.2012.718329.Challenges
- https://doi.org//10.3389/fimmu.2019.00231
- https://doi.org//10.1017/S0007114515002093
- https://doi.org//10.1111/jdi.12657
- https://doi.org//10.1111/liv.12385
- https://doi.org//10.3389/fphys.2018.00132
- https://doi.org//10.1007/s00404-017-4617-0
- https://doi.org//10.1016/j.mce.2013.06.010
- https://doi.org//10.1016/j.cardiores.2005.12.002
- https://doi.org//10.1002/dmrr.3029
- https://doi.org//10.1093/emph/eow014
- https://doi.org//10.1001/jama.286.3.327
- https://doi.org//10.1016/j.trstmh.2008.04.010
- https://doi.org//10.3389/fphys.2020.578966
- https://doi.org//10.1080/08037051.2016.1249336
- https://doi.org//10.1016/S0140-6736%2818%2932203-7
- https://doi.org//10.1186/s10020-018-0047-0
- https://doi.org//10.1111/j.1464-5491.2008.02584.x
- https://doi.org//10.1253/circj.CJ-09-0057
- https://doi.org//10.1038/s41574-020-00462-1
- https://doi.org//10.3389/fphys.2019.01399
- https://doi.org//10.1016/j.molimm.2005.06.018
- https://doi.org//10.2337/diabetes.54.10.2932
- https://doi.org//10.1038/s41540-018-0056-1
- https://doi.org//10.1016/j.metabol.2021.154873
- https://doi.org//10.3390/cells9092014
- https://doi.org//10.1210/jcem.87.4.8381
- https://doi.org//10.1016/j.cgh.2019.11.050
- https://doi.org//10.1186/1755-8794-7-35
CC BY 4.0